Last reviewed · How we verify
Xiaflex (collagenase)
At a glance
| Generic name | collagenase |
|---|---|
| Sponsor | Advance Biofactures |
| Drug class | Collagen-specific Enzyme |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
- Dupuytren's disease of finger, with contracture
- Induratio penis plastica
Common side effects
- Hypersensitivity
- Fatigue
Key clinical trials
- Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease (PHASE4)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Pilot Study on the Efficacy and Safety of FIBRORESTIL® as an Adjuvant Intralesional Treatment in Patients With Peyronie's Disease Receiving Standard Therapy (NA)
- Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease (NA)
- Collagenase Biobank Study
- A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA) (PHASE2)
- Can the Number of Skin Tears be Reduced, by Prophylactic Treatment of the Skin in Dupuytrens Contracture Treated With Collagenase? (NA)
- The Effect of Stromal Vascular Fraction Transplantation on the Regeneration of Expanded Skin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xiaflex CI brief — competitive landscape report
- Xiaflex updates RSS · CI watch RSS
- Advance Biofactures portfolio CI